Biohaven CEO Vlad Coric

Months in­to boom­ing acute mi­graine launch, Bio­haven chas­es pre­ven­tion with oral CGRP med Nurtec ODT

In the sud­den­ly bustling mar­ket for CGRP acute mi­graine fight­ers, Bio­haven has tout­ed its Nurtec ODT as an ob­vi­ous choice for pa­tients with its fast dis­solv­ing oral for­mu­la­tion. De­spite hit­ting the oral mar­ket sec­ond, Nurtec is keep­ing pace with its im­me­di­ate ri­val and is an­gling for even big­ger fish in pre­ven­tion.

In Phase III da­ta pub­lished Tues­day in The Lancet, Bio­haven’s Nurtec cut pa­tient’s av­er­age mi­graine days by 4.3 per month com­pared with place­bo and sliced the num­ber of mod­er­ate-to-se­vere mi­graines per month by more than 50%.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.